Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Neurofibromatosis 1 9Melanoma 6Neurofibroma, Plexiform 5Pancreatic Neoplasms 3Lung Neoplasms 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Thyroid Cancer, Papillary 2Sarcoma 2Neurofibrosarcoma 2Gallbladder Neoplasms 2Bile Duct Neoplasms 2Uveal Melanoma 1Thymoma 1Small Cell Lung Carcinoma 1Recurrence 1Peripheral Nervous System Diseases 1Non-small Cell Lung Cancer Metastatic 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neuroblastoma 1Neoplasms, Nerve Tissue 1Neoplasm Metastasis 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1

Interventions

Glutamine 2sagopilone 1nicotinamide-beta-riboside 1allantoicase 1Vitamin D 1Vitamin B 6 1Vitamin B 12 1Taxoids 1Tadalafil 1Sirolimus 1Prednisolone 1Paclitaxel 1Minocycline 1Metformin 1Losartan 1Hydroxychloroquine 1G(M1) Ganglioside 1Fatty Acids, Omega-3 1Exercise 1Everolimus 1Etoricoxib 1Ethosuximide 1Epoetin Alfa 1Dietary Supplements 1Dexamethasone 1Cryotherapy 1Bortezomib 1BID protein, human 1Acupuncture Therapy 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Peripheral Nervous System Diseases × AZD 6244 × Clear all
NCT03109301 2019-04-05

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
CNS

Neoplasms, Nerve Tissue, Neurofibromatosis 1, Peripheral Nervous System Diseases, Neurofibroma, Plexiform, Heredodegenerative Disorders, Nervous System

Data powered by HemOnc (CC BY 4.0) Colophon âš¡